Kaposi’s Sarcoma Market to Observe Stunning Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Vasgene, BMS

 Breaking News
  • No posts were found

Kaposi’s Sarcoma Market to Observe Stunning Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Vasgene, BMS

March 23
03:43 2023
Kaposi's Sarcoma Market to Observe Stunning Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Vasgene, BMS
Delveinsight Business Research LLP
As per DelveInsight, the Kaposi’s Sarcoma Market dynamics are anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies.

Key players, such as Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and others, are active in the Kaposi’s Sarcoma therapeutics domain. The emerging therapies which are under development are expected to provide efficient therapeutic approaches with a novel mechanism of action for the treatment of patients affected with Kaposi’s Sarcoma

DelveInsight’s “Kaposi’s Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Kaposi’s Sarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Kaposi’s Sarcoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Kaposi’s Sarcoma: An Overview

Kaposi’s Sarcoma (KS) is a multi-centric vascular tumor originating in the endothelial cells that line blood vessels and lymphatic vessels. KS is caused when tiny blood vessels develop below the surface of the skin, in the mouth, nose, eyes, or other parts of the body, such as the lymph nodes or lungs. Individuals with weak immune systems, especially HIV patients, have a high risk of Kaposi’s Sarcoma. The lesions of Kaposi’s Sarcoma typically appear as painless purplish spots on the feet, legs, face, genital area, mouth, or lymph nodes. In severe Kaposi’s Sarcoma, lesions may develop in the lungs and digestive tract.

Kaposi’s Sarcoma is caused by infection with a virus called Kaposi sarcoma-associated herpesvirus (KSHV), which is also known as herpesvirus 8 (HHV8). KSHV is in the same family as Epstein-Barr virus (EBV), the virus that causes infectious mononucleosis (mono) and is linked to several types of cancer.

There are four main forms of Kaposi’s Sarcoma: Epidemic or AIDS-associated KS, Classic KS, Endemic KS, and Immunosuppressive Kaposi’s Sarcoma. All forms of Kaposi’s Sarcoma (KS) are more common in men than in women.

Kaposi’s Sarcoma Market Key Facts

  • As per Globocan (2020), the prevalence rate of Kaposi Sarcoma is 1.11 per 100,000 in the United States, and its prevalence in the United Kingdom and Japan was found to be around 0.81/100,000 and 0.13/100,000, respectively.

  • As per the study titled “Risk of Kaposi’s Sarcoma after solid organ transplantation in the United States” conducted by Cahoon et al. (2018), KS incidence was 87% higher in men than women, over twofold greater in non-whites than whites, and two-fold higher in non‐US citizens than US citizens. KS incidence increased with age at transplant and decreased sharply with time since transplant, so the highest incidence occurred within 1 year of transplant.

  • KS was a rare disease before the AIDS epidemic in the early 1980s when the reported incidence of classic KS ranged from 0.01 per 100,000 person-years for the UK and 0.2 per 100,000 person-years for the USA.  The incidence of KS is currently reported to be ~200.

Kaposi’s Sarcoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Kaposi’s Sarcoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Kaposi’s Sarcoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Kaposi’s Sarcoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Kaposi’s Sarcoma Epidemiology, Segmented as –

  • Prevalent cases of Kaposi’s Sarcoma in 7MM [2019–2032]

  • Total Diagnosed cases of Kaposi’s Sarcoma in the 7MM [2019–2032]

  • Age-specific Cases of Kaposi’s Sarcoma in 7MM [2019–2032]

  • Total Treated Cases of Kaposi’s Sarcoma in 7MM [2019–2032]

  • Gender-specific Cases of Kaposi’s Sarcoma in 7MM [2019–2032]

Kaposi’s Sarcoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Kaposi’s Sarcoma market or expected to be launched during the study period. The analysis covers the Kaposi’s Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Kaposi’s Sarcoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Kaposi’s Sarcoma Market Will Evolve and Grow by 2032 @ 


Kaposi’s Sarcoma Therapeutics Analysis

The main forms of treatment for Kaposi’s Sarcoma are Antiretroviral Therapy, Surgery, Photodynamic Therapy, Radiation Therapy, and therapies using medications such as Chemotherapy, Topical medications, Targeted Therapy, and Immunotherapy.

At present, very few companies have initiated clinical trials that investigate new treatment options. Key players such as Vasgene Therapeutics (sEphB4-HAS), Bristol-Myers Squibb (Nivolumab and Ipilimumab), and several others are investigating their candidates for the management of Kaposi’s Sarcoma in the 7MM. Currently, Vasgene Therapeutics is leading the therapeutics market with its Kaposi’s sarcoma drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Kaposi’s Sarcoma Therapeutics Market Include:

  • Vasgene Therapeutics

  • Bristol Myers Squibb

  • SkinDermic

  • Aphios

  • TTY Biopharm

  • NeoImmuneTech

  • Cello Therapeutics

And Many Others

Kaposi’s sarcoma Emerging and Marketed Drugs Covered in the Report Include:

  • sEphB4-HAS: Vasgene Therapeutics

  • Nivolumab and Ipilimumab: Bristol-Myers Squibb

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Kaposi’s Sarcoma Competitive Intelligence Analysis

4. Kaposi’s Sarcoma Market Overview at a Glance

5. Kaposi’s Sarcoma Disease Background and Overview

6. Kaposi’s Sarcoma Patient Journey

7. Kaposi’s Sarcoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Kaposi’s Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Kaposi’s Sarcoma Unmet Needs

10. Key Endpoints of Kaposi’s Sarcoma Treatment

11. Kaposi’s Sarcoma Marketed Products

12. Kaposi’s Sarcoma Emerging Drugs and Latest Therapeutic Advances

13. Kaposi’s Sarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Kaposi’s Sarcoma Market Outlook (In US, EU5, and Japan)

16. Kaposi’s Sarcoma Access and Reimbursement Overview

17. KOL Views on the Kaposi’s Sarcoma Market

18. Kaposi’s Sarcoma Market Drivers

19. Kaposi’s Sarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles